摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-chlorophenoxy)-6-methoxy-4-methylquinolin-8-amine | 158430-86-5

中文名称
——
中文别名
——
英文名称
5-(4-chlorophenoxy)-6-methoxy-4-methylquinolin-8-amine
英文别名
——
5-(4-chlorophenoxy)-6-methoxy-4-methylquinolin-8-amine化学式
CAS
158430-86-5
化学式
C17H15ClN2O2
mdl
——
分子量
314.771
InChiKey
HXQBFPBFRNLEOC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.58
  • 重原子数:
    22.0
  • 可旋转键数:
    3.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    57.37
  • 氢给体数:
    1.0
  • 氢受体数:
    4.0

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs
    摘要:
    8-Aminoquinolines (8-AQs) are important class of anti-infective therapeutics. 5-Phenoxy 8-aminoquinoline analogs have shown improved metabolic stability compared to primaquine. In view or predictive role of monoamine oxidases (MAO) in metabolism of 8-aminoquinolines the 5-phenoxy analogs were evaluated in vitro for the inhibition of recombinant human MAO-A and MAO-B. The analogs were several folds more potent inhibitors of MAO-A and MAO-B compared to primaquine, the parent drug, with selectivity for MAO-B. 5-(4-Trifluoromethylphenoxy)-4-methylprimaquine (6) Inhibited MAO-B with IC50 value of 150 nM (626-fold more potent than primaquine). These results will have important implications in optimizing metabolic stability of 8-AQs to improve therapeutic value and also indicate scope for development of 8-AQs as selective MAO inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.12.108
  • 作为产物:
    描述:
    盐酸磷酸 、 palladium on activated charcoal 、 一水合肼 作用下, 以 乙醇 为溶剂, 生成 5-(4-chlorophenoxy)-6-methoxy-4-methylquinolin-8-amine
    参考文献:
    名称:
    Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs
    摘要:
    8-Aminoquinolines (8-AQs) are important class of anti-infective therapeutics. 5-Phenoxy 8-aminoquinoline analogs have shown improved metabolic stability compared to primaquine. In view or predictive role of monoamine oxidases (MAO) in metabolism of 8-aminoquinolines the 5-phenoxy analogs were evaluated in vitro for the inhibition of recombinant human MAO-A and MAO-B. The analogs were several folds more potent inhibitors of MAO-A and MAO-B compared to primaquine, the parent drug, with selectivity for MAO-B. 5-(4-Trifluoromethylphenoxy)-4-methylprimaquine (6) Inhibited MAO-B with IC50 value of 150 nM (626-fold more potent than primaquine). These results will have important implications in optimizing metabolic stability of 8-AQs to improve therapeutic value and also indicate scope for development of 8-AQs as selective MAO inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2011.12.108
点击查看最新优质反应信息

文献信息

  • Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs
    作者:Narayan D. Chaurasiya、Shobana Ganesan、N.P. Dhammika Nanayakkara、Luiza R.S. Dias、Larry A. Walker、Babu L. Tekwani
    DOI:10.1016/j.bmcl.2011.12.108
    日期:2012.2
    8-Aminoquinolines (8-AQs) are important class of anti-infective therapeutics. 5-Phenoxy 8-aminoquinoline analogs have shown improved metabolic stability compared to primaquine. In view or predictive role of monoamine oxidases (MAO) in metabolism of 8-aminoquinolines the 5-phenoxy analogs were evaluated in vitro for the inhibition of recombinant human MAO-A and MAO-B. The analogs were several folds more potent inhibitors of MAO-A and MAO-B compared to primaquine, the parent drug, with selectivity for MAO-B. 5-(4-Trifluoromethylphenoxy)-4-methylprimaquine (6) Inhibited MAO-B with IC50 value of 150 nM (626-fold more potent than primaquine). These results will have important implications in optimizing metabolic stability of 8-AQs to improve therapeutic value and also indicate scope for development of 8-AQs as selective MAO inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多